Interleukin-6 inhibitors in the treatment of rheumatoid arthritis

This publication has 29 references indexed in Scilit:

• Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study
  Annals of the Rheumatic Diseases, 2009
• The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis
  Expert Opinion on Biological Therapy, 2008
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
  The Lancet, 2008
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
  Annals of the Rheumatic Diseases, 2007
• The IL-6/sIL-6R complex as a novel target for therapeutic approaches
  Expert Opinion on Therapeutic Targets, 2007
• Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
  Arthritis & Rheumatism, 2006
• Effects of Anti‐TNF‐α Treatment on Lipid Profile in Patients with Active Rheumatoid Arthritis
  Annals of the New York Academy of Sciences, 2006
• Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trial
  Arthritis & Rheumatism, 2004
• Principles of interleukin (IL)-6-type cytokine signalling and its regulation
  Biochemical Journal, 2003
• REMISSION IN A PROSPECTIVE STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS. AMERICAN RHEUMATISM ASSOCIATION PRELIMINARY REMISSION CRITERIA IN RELATION TO THE DISEASE ACTIVITY SCORE
  Rheumatology, 1995